IONS IONIS PHARMACEUTICALS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 874015 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-0.7%
TTM net income YoY-113.2%
TTM EPS YoY-96.4%
Revenue 3-yr CAGR16.0%
Net income 3-yr CAGR—
Margins
Gross margin98.2%
Operating margin-58.8%
Net margin-56.9%
FCF margin-64.2%
EBITDA margin-57.4%
Returns
ROE-108.1%
ROA-18.4%
ROIC (approx.)-236.8%
Asset turnover0.32x
Leverage & solvency
Liabilities / assets86.5%
Debt / equity0.00x
Current ratio5.43x
Interest coverage-29.37x
Cash quality & payout
Operating cash flow / net income1.00x
Accruals ratio-0.1%
Payout ratio—
Capex / revenue7.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $943.71M | $705.14M |
| Cost of revenue | $15.91M | $11.21M |
| Gross profit | $927.80M | $693.92M |
| R&D expense | $915.62M | $901.53M |
| SG&A expense | $393.87M | $267.47M |
| Operating income | -$381.68M | -$475.08M |
| Interest expense | $17.26M | $16.99M |
| Pretax income | -$379.60M | -$460.07M |
| Income tax | $1.79M | -$6.17M |
| Net income | -$381.39M | -$453.90M |
| EBITDA | -$371.68M | -$465.47M |
| EPS (basic) | -2.38 | -3.04 |
| EPS (diluted) | -2.38 | -3.04 |
| Weighted avg. shares (diluted) | 160.01M | 149.51M |
| Balance sheet | ||
| Cash & equivalents | $372.26M | $242.08M |
| Short-term investments | $2.31B | $2.06B |
| Inventory | $10.05M | $12.51M |
| Current assets | $2.99B | $2.62B |
| PP&E, net | $123.05M | $94.25M |
| Total assets | $3.52B | $3.00B |
| Current liabilities | $781.57M | $309.32M |
| Short-term debt | $432.12M | $165,000 |
| Long-term debt | $1.33B | $1.20B |
| Total debt | $1.76B | $1.20B |
| Total liabilities | $3.03B | $2.42B |
| Shareholders' equity | $489.09M | $588.35M |
| Net debt | $1.39B | $960.49M |
| Shares outstanding | 163.30M | 157.91M |
| Cash flow statement | ||
| Operating cash flow | -$268.58M | -$500.95M |
| Capital expenditure | $51.44M | $45.28M |
| Free cash flow | -$320.03M | -$546.23M |
| Investing cash flow | -$277.78M | -$134.03M |
| Financing cash flow | $675.84M | $478.06M |
| Depreciation & amortization | $10.01M | $9.61M |
| Stock-based compensation | $133.87M | $130.20M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.